51. Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia
- Author
-
Kristina Tomic, Darko Antic, Vojin Vukovic, Biljana Mihaljevic, and Teodora Karan-Đurašević
- Subjects
Computer Networks and Communications ,business.industry ,Chronic lymphocytic leukemia ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Hardware and Architecture ,030220 oncology & carcinogenesis ,Cancer research ,tp53 aberrations ,Mutational status ,Medicine ,chronic lymphocytic leukemia ,Clinical significance ,ighv mutational status ,IGHV@ ,business ,Software ,030215 immunology - Abstract
Chronic lymphocytic leukemia (CLL) is a very heterogeneous disease with a variable clinical course. On the one side of the spectrum, there are patients with aggressive and resistant disease, of which they die only a few months after diagnosis while, on the other side, there are patients with an indolent, slowly progressive disease that does not require treatment for decades. The reasons for this are only partially known, but they have been the subject of numerous scientific studies during the last several decades. Consequently, the concept of prognostic and predictive factors in CLL have emerged, which aims to predict the clinical course and its therapeutic outcome. With the improvement of understanding the pathophysiology of this disease, the lists of prognostic and predictive factors are getting longer every year, but they also overlap. In this review, we singled out the aberrations of the TP53 gene and the IGHV (immunoglobulin heavy variable) gene mutational status as the two most important and most studied factors that have both prognostic and predictive significance.
- Published
- 2020